Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
WEST PHARMACEUTICAL SERVICES INC
Bear Case (25th pct.)
-78.2% vs price
Base Case (Median)
-67.7% vs price
Bull Case (75th pct.)
-65.4% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $65.13 | -82.2% | High (40%) |
| PE Comparable | $175.37 | -52.0% | Medium (25%) |
| Growth Trajectory DCF | $122.58 | -66.4% | Medium (20%) |
| Graham Number | $88.79 | -75.7% | Medium (40%) |
| EV/EBITDA | $117.76 | -67.7% | Medium (20%) |
| EV/FCF | $129.99 | -64.4% | Medium (20%) |
| Earnings Power Value | $70.58 | -80.7% | Medium (50%) |
Based on 7 out of 7 methods, WST appears overvalued at the current price of $364.98. The base case fair value of $117.76 implies 67.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.